{"id":"W2136977965","doi":"10.1200/jco.2007.15.9947","title":"Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":510,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Genentech; American Society of Clinical Oncology","keywords":"Medicine; Bevacizumab; Hepatocellular carcinoma; Internal medicine; Vascular endothelial growth factor; Gastroenterology; Angiogenesis; Oncology; Adverse effect; Phases of clinical research; Clinical trial; Chemotherapy; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01010604,0.0001986946,0.002309827,0.0001639845,0.0001194696,0.000004371761,0.0002013064,0.0005821028,0.00004982854],"category_scores_gemma":[0.01280371,0.0001113013,0.0007920848,0.0002577998,0.000741004,0.00008037224,0.0001269421,0.001275356,0.000004058965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006531567,"about_ca_system_score_gemma":0.001856186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004807187,"about_ca_topic_score_gemma":0.000008579749,"domain_scores_codex":[0.9925362,0.002671067,0.003768071,0.000285773,0.0004265958,0.000312241],"domain_scores_gemma":[0.9881065,0.009186596,0.001772338,0.000283536,0.0003270813,0.0003239289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.08437687,0.007767074,0.8354099,0.00005293622,0.0002628545,0.002748214,0.000198561,2.874822e-7,0.0004573399,0.00002173328,0.0002493968,0.06845483],"study_design_scores_gemma":[0.3689402,0.4182696,0.203093,0.0001610559,0.001061898,0.0008910018,0.00007255894,0.00359278,0.001095523,0.0003475517,0.002320949,0.0001538886],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918563,0.004062396,0.00001852819,0.001603264,0.001083479,0.001076264,0.000001666317,0.000006355504,0.0002917293],"genre_scores_gemma":[0.9956685,0.001551639,0.001166252,0.0003813458,0.001091401,0.00001950088,0.000003254324,0.00001558457,0.0001024742],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6323169,"threshold_uncertainty_score":0.9955118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4016800966902733,"score_gpt":0.4960715878263401,"score_spread":0.09439149113606682,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}